Close Menu

NEW YORK (GenomeWeb) – Trovagene announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Illinois, establishing access for plan members to the company's full line of Trovera liquid biopsy tests.

This product line currently includes assays performed on either blood or urine, which detect mutations in EGFR, KRAS, and BRAF.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.